Clinical Trials Browser

Nasopharyngeal Carcinoma × spartalizumab × Head & Neck × Clear all

NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT06475300 2026-05-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase 2 Recruiting

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06676293 2024-11-07

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

Phase NA Completed

Nasopharyngeal Carcinoma

NCT04557020 2024-05-01

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Phase 3 Unknown

Nasopharyngeal Carcinoma

NCT04830267 2024-03-28

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

122 enrolled 28 charts

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

NCT05092217 2021-10-25

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Recurrence